{"disease":{"id":"metastatic-myxoid-liposarcoma","name":"metastatic myxoid liposarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03063632","title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03670069","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06414434","title":"BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Michael Wagner, MD","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}